Brief: Qyuns Therapeutics Says New Drug Application Of Crusekitug (Qx002n) Accepted By NMPA
09/03/2026 15:33
March 9 (Reuters) - Qyuns Therapeutics Co Ltd 2509.HK: NEW DRUG APPLICATION OF CRUSEKITUG (QX002N) FOR TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS IN ADULTS ACCEPTED BY NMPA Further company coverage: 2509.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Qyuns Therapeutics
See all newsBrief: QYUNS Therapeutics Posts HY Adjusted Profit Of RMB202.5 MLN
Brief: Qyuns Therapeutics Says Qx027n Obtains Two Clinical Trial Approvals For Copd, Chronic Rhinosinusitis
Brief: Qyuns Therapeutics Says Saifu Juli To Buy 34% Of Cellularforce For RMB86.02 Million
Brief: Qyuns Therapeutics Repurchases 3.43 Million Shares As Treasury Shares From Nov 6, 2025 To June 9
Brief: Qyuns Therapeutics Co Receives Milestone Payment From Roche